SCHEMBL21664230

SCHEMBL21664230

CS(=O)(=O)NC1CCCN(c2ncnc3ccccc23)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ HTT P42858 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ AKT1 P31749 2/20 0.49
▸ HRH1 P35367 1/20 0.49
▸ HRH3 Q9Y5N1 1/20 0.49
▸ HRH4 Q9H3N8 1/20 0.48
▸ DOT1L Q8TEK3 1/20 0.47
▸ PDE10A Q9Y233 1/20 0.47
▸ GBA1 P04062 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ OPRM1 P35372 1/20 0.46
▸ OPRD1 P41143 1/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ OGFRL1 Q5TC84 1/20 0.46
▸ ATR Q13535 2/20 0.46
▸ ATRIP Q8WXE1 2/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ ENPP1 P22413 1/20 0.45
▸ PTK2 Q05397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21664234 0.85 CNR1 (0.55) HTTAKT1HRH4DOT1LATR
SCHEMBL30562857 0.85 HTT (0.49) LMNAHTTAKT1DOT1LATR
SCHEMBL21664236 0.85 ENPP1 (0.47) AKT1DOT1LATRATRIPENPP1
SCHEMBL30562921 0.85 CNR1 (0.55) HTTAKT1HRH4DOT1LATR
SCHEMBL21664232 0.85 HTT (0.49) LMNAHTTAKT1DOT1LATR
SCHEMBL21664309 0.83 LMNA (0.50) LMNAHTTSMN1; SMN2HRH1HRH3
SCHEMBL26561064 0.82 LMNA (0.54) LMNAHTTSMN1; SMN2HRH1HRH3
SCHEMBL30562900 0.82 CNR1 (0.51) AKT1HRH4DOT1LRAB9AATR
SCHEMBL21664322 0.82 CNR1 (0.51) AKT1HRH4DOT1LRAB9AATR
SCHEMBL21664239 0.82 ENPP1 (0.51) AKT1DOT1LPDE10AATRATRIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551188-B1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RES INST (US) 2023-10-18 — — EP disclosed
EP-3551188-B1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RES INST (US) 2023-10-18 — — EP disclosed
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2023-09-12 — — US disclosed
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2023-09-12 — — US disclosed
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2023-06-08 — — US disclosed
US-11524010-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2022-12-13 — — US disclosed
US-20210369713-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2021-12-02 — — US disclosed
US-20200038402-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200038402-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXN2, TXNRD1 LMNA 3152/4885HTT 2298/4885SMN1; SMN2 3996/4885
US-11524010-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 LMNA 3252/4885HTT 1236/4885SMN1; SMN2 4100/4885
US-20210369713-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXNL1, TXN2 LMNA 3252/4885HTT 1236/4885SMN1; SMN2 4100/4885
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXNL1, TXN2 LMNA 3252/4885HTT 1236/4885SMN1; SMN2 4100/4885
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 LMNA 3252/4885HTT 1236/4885SMN1; SMN2 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback